| ECFS best practice guidelines: the 2018 revision C Castellani, AJA Duff, SC Bell, HGM Heijerman, A Munck, F Ratjen, ... Journal of cystic fibrosis 17 (2), 153-178, 2018 | 728 | 2018 |
| A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis JA Baugh, S Chitnis, SC Donnelly, J Monteiro, X Lin, BJ Plant, F Wolfe, ... Genes & Immunity 3 (3), 170-176, 2002 | 467 | 2002 |
| VX-659–tezacaftor–ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles JC Davies, SM Moskowitz, C Brown, A Horsley, MA Mall, EF McKone, ... New england journal of medicine 379 (17), 1599-1611, 2018 | 340 | 2018 |
| The effects of freezing on faecal microbiota as determined using MiSeq sequencing and culture-based investigations F Fouhy, J Deane, MC Rea, Ó O’Sullivan, RP Ross, G O’Callaghan, ... PloS one 10 (3), e0119355, 2015 | 314 | 2015 |
| Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST) EF McKone, D Borowitz, P Drevinek, M Griese, MW Konstan, ... The lancet Respiratory medicine 2 (11), 902-910, 2014 | 236 | 2014 |
| The altered gut microbiota in adults with cystic fibrosis DG Burke, F Fouhy, MJ Harrison, MC Rea, PD Cotter, O O’Sullivan, ... BMC microbiology 17, 1-11, 2017 | 155 | 2017 |
| A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis R Cosgriff, S Ahern, SC Bell, K Brownlee, PR Burgel, C Byrnes, H Corvol, ... Journal of cystic fibrosis 19 (3), 355-358, 2020 | 147 | 2020 |
| Management of comorbidities in older patients with cystic fibrosis BJ Plant, CH Goss, WD Plant, SC Bell The Lancet Respiratory Medicine 1 (2), 164-174, 2013 | 118 | 2013 |
| Bacterial cis-2-unsaturated fatty acids found in the cystic fibrosis airway modulate virulence and persistence of Pseudomonas aeruginosa KB Twomey, OJ O'connell, Y McCarthy, JM Dow, GA O'toole, BJ Plant, ... The ISME journal 6 (5), 939-950, 2012 | 111 | 2012 |
| The global impact of SARS-CoV-2 in 181 people with cystic fibrosis E McClenaghan, R Cosgriff, K Brownlee, S Ahern, PR Burgel, CA Byrnes, ... Journal of cystic fibrosis 19 (6), 868-871, 2020 | 102 | 2020 |
| Cystic fibrosis, disease severity, and a macrophage migration inhibitory factor polymorphism BJ Plant, CG Gallagher, R Bucala, JA Baugh, S Chappell, L Morgan, ... American journal of respiratory and critical care medicine 172 (11), 1412-1415, 2005 | 98 | 2005 |
| CORK study in cystic fibrosis: sustained improvements in ultra-low-dose chest CT scores after CFTR modulation with ivacaftor NJ Ronan, GG Einarsson, M Twomey, D Mooney, D Mullane, ... Chest 153 (2), 395-403, 2018 | 97 | 2018 |
| Effects of ivacaftor in patients with cystic fibrosis who carry the G551D mutation and have severe lung disease PJ Barry, BJ Plant, A Nair, S Bicknell, NJ Simmonds, NJ Bell, NT Shafi, ... Chest 146 (1), 152-158, 2014 | 95 | 2014 |
| Radiologic imaging in cystic fibrosis: cumulative effective dose and changing trends over 2 decades OJ O'Connell, S McWilliams, AM McGarrigle, OJ O'Connor, F Shanahan, ... Chest 141 (6), 1575-1583, 2012 | 91 | 2012 |
| Microbiota and metabolite profiling reveal specific alterations in bacterial community structure and environment in the cystic fibrosis airway during exacerbation KB Twomey, M Alston, SQ An, OJ O'Connell, Y McCarthy, D Swarbreck, ... PloS one 8 (12), e82432, 2013 | 83 | 2013 |
| Current and emerging comorbidities in cystic fibrosis NJ Ronan, JS Elborn, BJ Plant La Presse Médicale 46 (6), e125-e138, 2017 | 82 | 2017 |
| Inhaled versus nebulised tobramycin: a real world comparison in adult cystic fibrosis (CF) MJ Harrison, M McCarthy, C Fleming, C Hickey, C Shortt, JA Eustace, ... Journal of Cystic Fibrosis 13 (6), 692-698, 2014 | 68 | 2014 |
| A study to assess inhaler technique and its potential impact on asthma control in patients attending an asthma clinic CM Harnett, EB Hunt, BR Bowen, OJ O’Connell, DM Edgeworth, ... Journal of Asthma 51 (4), 440-445, 2014 | 66 | 2014 |
| Longitudinal trends in real-world outcomes after initiation of ivacaftor. A cohort study from the cystic fibrosis registry of Ireland L Kirwan, G Fletcher, M Harrington, P Jeleniewska, S Zhou, B Casserly, ... Annals of the American Thoracic Society 16 (2), 209-216, 2019 | 60 | 2019 |
| Ivacaftor in a G551D homozygote with cystic fibrosis MJ Harrison, DM Murphy, BJ Plant New England Journal of Medicine 369 (13), 1280-1282, 2013 | 54 | 2013 |
